Gretchen Evans
Foot Surgery · Peoria, ILNPI 1477504710
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 99 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Smith+Nephew accounts for 68.9% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2019 at $624 and has fallen 75.3% since, to $154 in 2025.
Across 99 payments — averaging $19.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$1K
- Osiris Therapeutics Inc.$173
- Johnson & Johnson$60
- Organogenesis Inc.$54
- Takeda Pharmaceuticals U.S.A., Inc.$43
- Abbott$38
- plus $246 from 11 others
What the payments were for
- Food & beverage$1,976100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 68 | $1,361 |
| Osiris Therapeutics Inc. | 8 | $173 |
| Johnson & Johnson(2 entities) | 2 | $60 |
| Organogenesis Inc. | 3 | $54 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $43 |
| Abbott | 2 | $38 |
| Cashflow Solutions, LLC | 2 | $35 |
| Melinta Therapeutics, LLC | 2 | $33 |
| Orthofix Medical, Inc. | 2 | $26 |
| Stryker | 1 | $26 |
| Pacira Pharmaceuticals Incorporated | 1 | $24 |
| Polynovo North America LLC | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Misonix Inc | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Merck | 1 | $12 |
| AstraZeneca | 1 | $12 |
How this compares
$1,976 in reported general payments places this provider in the 65th percentile of 51 foot surgery providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clotrimazole | 12 | $280 |
| Gabapentin | 30 | $268 |
| Terbinafine Hcl | 29 | $217 |
| Meloxicam | 36 | $215 |
| Tramadol Hcl | 28 | $97 |
| Clindamycin Hcl | 23 | $78 |
Paid to pharmacies, not to this prescriber.
Other foot surgery in Peoria
- Peter LyPeoria$55
- Jeeten SinghaWestmont$14K
- Christopher AndersonO'Fallon$13K
- Stephanie WuNorth Chicago$7K
- Jillian CabaiChicago$7K
- William FinnOak Park$5K
- Jeremiah BushmakerGalesburg$5K
- Cory JacobyElgin$4K
- Syed HussainHoffman Estates$4K
- Edward UramDowners Grove$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.